Hana Biosciences Receives Orphan Drug Designation for Ropidoxuridine (IPdR), for the Treatment of Malignant Glioma and GTx, Inc. to Present at Goldman Sachs Twenty-Seventh Annual Global Healthcare Conference.

0 Comments | M2 Presswire, June, 2006

M2 PRESSWIRE-9 June 2006-U.S. Equity News: Hana Biosciences Receives Orphan Drug Designation for Ropidoxuridine (IPdR), for the Treatment of Malignant Glioma and GTx, Inc. to Present at Goldman Sachs Twenty-Seventh Annual Global Healthcare Conference(C)1994-2006 M2 COMMUNICATIONS LTD RDATE:09062006 City of Industry, CA - U.S.

Equity News provideds Biotechnology industry news alert. Hana Biosciences (Nasdaq: HNAB), a biopharmaceutical company focused on advancing cancer care, announced that the U.S. Food and Drug Administration has granted orphan drug designation for Ropidoxuridine (IPdR) for the treatment of malignant glioma, which makes up approximately half of all primary brain tumors. Ropidoxuridine is a novel, orally available, thymidine analogue and...

Read the rest of this article with a Free Trial at HighBeam Research.
Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:
  1. You are currently: a Guest |
  4.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)